Kaitlyn Bader, Associate Editor

Abstracts will include updates on treatment for psoriatic arthritis, psoriasis, atopic dermatitis, and more.

Timber Pharmaceuticals’ CONTROL study evaluated the safety and efficacy of the topical isotretinoin.

This week's edition of the Mainstream Patient features stories about tattoo aftercare, expert-reviewed wrinkle creams, trending Latinx beauty brands, and more.

ICYMI, this week we had stories about adherence issues in acne treatment, shin guard dermatitis, atopic dermatitis in skin of color patients, clinical trial news from Arcutis Biotherapeutics, and more.

INTEGUMENT-1 and 2 trial data for atopic dermatitis are expected at the end of 2022.

Peter Lio, MD, clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.

Emergency Use Authorization provides a 2-dose primary series given 3 weeks apart.

This week's edition of the Mainstream Patient features stories about psoriasis in skin of color, the best facial cleansing brushes, a new acne-focused skin care line, Joe Jonas' experience with injectables, and more.

ICYMI, this week we had stories about psoriasis and tattoos, shin guard dermatitis, rosacea symptoms, a new treatment option for severe burns, and more.

MediWound’s new burn care therapy alleviates risks associated with surgical debridement.

Survey participants state persistent facial redness is one of the most frustrating rosacea symptoms.

In this episode, Peter Lio, MD, and clinical professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine, discusses how atopic dermatitis presents differently in pediatric patients, and the 2021 allergen of the year, acetophenone azine associated with shin guard dermatitis.

This week's edition of the Mainstream Patient features stories about adult acne, Native American beauty products, a non-irritating retinol serum, beauty brands that support abortion rights, and more.

ICYMI, this week we had stories about product recalls, FDA warning letters, pediatric atopic dermatitis, acne treatment, and more.

VYNE Therapeutics Inc. announced the results of study VY2021-01.

Amazon, Ariella Naturals, and Justified Laboratories received warning letters from the FDA.

Edgewell Personal Care Company issued a voluntary national recall of 3 collections of Banana Boat Hair & Scalp Sunscreen due to the presence of benzene.

This week's edition of the Mainstream Patient features stories about hormonal acne, body scrubs, vitamin C serum to fight hyperpigmentation, and more.

ICYMI, this week we had stories about FDA approvals, biologics vs biosimilars, CTCL treatment, atopic dermatitis in patients with skin of color, and more.

Soligenix announces positive phase 3 results from FLASH study for the use of synthetic hypericin to reduce cutaneous T-cell lymphoma lesions.

Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ustekinumab as a new treatment option for patients aged 6 years or older with active psoriatic arthritis.

This week's edition of the Mainstream Patient features stories about skin care for eczema, clean beauty misinformation, the Crown Act, skin care in space, and more.

Arcutis Biotherapeutics’ roflumilast cream will provide relief to patients aged 12 years or older diagnosed with plaque psoriasis.

Each month, Dermatology Times® features a roundup of products trending in skin care. Find out what products are trending for the month of July.

ICYMI, this week we had stories about legal issues in practices, sustainable skin care, acne scar treatments, monkeypox, and more.

This week's edition of the Mainstream Patient features stories about eye creams, gifts for pregnant women to enjoy, sleep cycles & heat waves, freckles, and more.

ICYMI, this week we had stories about skin cancer, FDA approvals, vitiligo, consumer trends, and more.

The American Academy of Dermatology Association shares its recommendations for anti-aging products and reducing skin aging.

Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.

Results published in the Journal of the American Medical Association (JAMA) Dermatology detailed the efficacy and safety of berdazimer gel 10.3%, in the treatment of molluscum contagiosum.